No Data
No Data
Jiangsu Skyray Instrument: Half-year report for the year 2024.
Jiangsu Skyray Instrument: Summary of Half-Year Report in 2024.
Jiangsu Skyray Instrument (300165.SZ) released its performance for the first half of the year, turning from profit to a loss of 14.8892 million yuan.
Jiangsu Skyray Instrument (300165.SZ) released its 2024 semi-annual report, with the company's revenue reaching 380 million yuan...
As of August 9th, 2024, Jiangsu Skyray Instrument's number of shareholders is 28,639.
Jiangsu Skyray Instrument (300165.SZ) stated on the investor interaction platform that as of the close of August 9, 2024, the number of shareholders in the company was 28,639.
Jiangsu Skyray Instrument (300165.SZ): The X fluorescence spectrometer is mainly used for the analysis of constant elements, trace elements and trace elements in various substances.
On July 22nd, Gelunhui reported that an investor asked Jiangsu Skyray Instrument (300165.SZ) on the investor interactive platform, "In which areas is your X fluorescence spectrometer mainly used, and how is its sales volume?" The company replied that its X fluorescence spectrometer is mainly used for component analysis of constant elements, trace elements, and trace elements in various substances. The application industry covers commodity testing, industrial testing and analysis, material testing, petrochemicals, food safety, environmental protection, scientific research and many other fields. Currently, the company's production of XRF (Energy Dispersive X-ray Fluorescence Spectrometer) has a high position in the field of spectral analysis instruments.
Tianrui Instruments (300165.SZ): Terminating the issuance of A-shares to specific targets in 2023
Gelonghui, May 22丨Tianrui Instrument (300165.SZ) announced that the company's termination of issuing A-shares to specific targets in 2023 was a prudent decision based on changes in the company's financing environment. The company's current production and operation are normal. The termination of the issuance of A-shares to specific targets will not have a significant adverse impact on the company's normal production and operation, and there are no circumstances that harm the interests of the company and all shareholders, especially small and medium shareholders.
No Data
No Data